Evidence map›Paper›PMID 30443293›Full record

ReviewOncotarget2018

Chemical modulation of autophagy as an adjunct to chemotherapy in childhood and adolescent brain tumors.

Juliette Servante, Jasper Estranero, Lisethe Meijer, Rob Layfield, Richard Grundy

Open access · diamondAbstract readReview
In one paragraph

Review in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. SGK1, autophagy and cancer: an overview.Molecular biology reports · 2022
    Review
  4. Article
  5. Autophagy in cancers including brain tumors: role of MicroRNAs.Cell communication and signaling : CCS · 2020
    Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Juliette ServanteSchool of Life Sciences, University of Nottingham, Medical School, Nottingham, NG7 2UH, UK.
Jasper EstraneroChildren's Brain Tumor Research Centre, Medical School, Queen's Medical Centre, Nottingham, NG7 2UH, UK.
Lisethe MeijerChildren's Brain Tumor Research Centre, Medical School, Queen's Medical Centre, Nottingham, NG7 2UH, UK.
Rob LayfieldSchool of Life Sciences, University of Nottingham, Medical School, Nottingham, NG7 2UH, UK.
Richard GrundyChildren's Brain Tumor Research Centre, Medical School, Queen's Medical Centre, Nottingham, NG7 2UH, UK.
Queen's Medical Centre · GBUniversity of Nottingham · GBBrain Tumour Research · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brain tumors are the leading cause of cancer-related death in children and are the most challenging childhood cancer in relation to diagnosis, treatment, and outcome. One potential novel strategy to improve outcomes in cancer involves the manipulation of autophagy, a fundamental process in all cells. In cancer, autophagy can be thought of as having a "Janus"-like duality. On one face, especially in the early phases of cancer formation, autophagy can act as a cellular housekeeper to eliminate damaged organelles and recycle macromolecules, thus acting as tumor suppressor. On the other face, at later stages of tumor progression, autophagy can function as a pro-survival pathway in response to metabolic stresses such as nutrient depravation, hypoxia and indeed to chemotherapy itself, and can support cell growth by supplying much needed energy. In the context of chemotherapy, autophagy may, in some cases, mediate resistance to treatment. We present an overview of the relevance of autophagy in central nervous system tumors including how its chemical modulation can serve as a useful adjunct to chemotherapy, and use this knowledge to consider how targeting of autophagy may be relevant in pediatric brain tumors.

Indexed as

autophagosomeautophagychildhood brain tumorschloroquinemTOR

Identifiers

PMID30443293
PMCPMC6219655
OpenAlexW2895873411

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.